Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) has announced that it will proceed with a Phase 3 trial evaluating the efficacy and safety of lenabasum for treating dermatomyositis. As quoted in the press release: Dermatomyositis is a rare and serious multisystem inflammatory autoimmune disease affecting muscle and skin. The U.S. Food and Drug Administration (“FDA”) provided guidance on … Continued